

Supplemental Table 1. Mean (SEM) concentration (pg/ μ L) of eicosanoids in suction blister fluid from unexposed and UVR-exposed skin at baseline and post-supplementation.

	Baseline				Post-supplementation			
	Active (<i>n</i> = 20)		Placebo (<i>n</i> = 21)		Active (<i>n</i> = 20)		Placebo (<i>n</i> = 21)	
	No UV	3 x MED	No UV	3 x MED	No UV	3 x MED	No UV	3 x MED
PGE ₂	55.6 (7.9)	96.2 (13.3)**	76.0 (16.0)	126.9 (20.1)*	57.5 (7.3)	114.2 (18.8)**	77.6 (14.0)	142.2 (16.3)**
PGE ₁ ^a	4.8 (0.8)	11.2 (1.4)**	7.6 (2.0)	16.6 (2.4)**	4.2 (0.6)	12.3 (2.0)**	6.3 (1.2)	16.4 (2.3)***
PGE ₃ ^b	5.6 (4.6)	1.2 (0.2)	0.8 (0.2)	1.8 (0.3)*	0.7 (0.1)	1.4 (0.4)*	0.7 (0.1)	2.5 (0.9)*
PGJ ₂ ^c	3.2 (0.5)	3.0 (0.4)	2.7 (0.5)	4.3 (0.5)	2.4 (0.3)	4.3 (0.7)*	2.3 (0.6)	4.9 (0.5)*
PGD ₁ ^d	0.6 (0.2)	0.4 (0.1)	0.6 (0.1)	0.6 (0.1)	0.4 (0.1)	0.4 (0.1)	0.7 (0.2)	0.7 (0.2)
PGD ₂ ^e	6.6 (1.1)	3.2 (0.4)**	8.3 (1.3)	4.5 (0.6)**	7.6 (1.3)	5.0 (1.1)*	9.6 (1.5)	4.5 (0.5)**
PGF _{2α} ^f	9.8 (1.9)	14.2 (2.2)	15.6 (2.7)	25.6 (3.4)*	9.2 (1.6)	27.6 (7.4)**	10.0 (1.3)	24.9 (3.2)***
13,14 dihydro-15-keto PGE ₂ ^e	15.4 (2.6)	4.3 (0.7)***	15.0 (2.0)	5.1 (0.8)***	15.5 (2.1)	5.3 (1.3)***	16.9 (3.2)	6.3 (1.0)**
13,14 dihydro-15-keto PGE ₁ ^g	0.9 (0.2)	0.5 (0.1)*	1.0 (0.2)	0.7 (0.1)	0.7 (0.2)	0.4 (0.1)	0.8 (0.2)	0.9 (0.3)
12-HETE ^h	20.2 (3.6)	40.3 (5.1)**	23.3 (4.6)	46.0 (5.3)**	18.6 (2.9)	43.1 (4.6)***	17.0 (3.7)	40.5 (4.9)**
11-HETE ^h	2.4 (0.4)	7.5 (0.8)***	3.5 (0.6)	9.3 (1.1)**	2.4 (0.3)	10.2 (1.6)***	2.8 (0.4)	9.2 (0.8)***
15-HETE ⁱ	4.6 (1.3)	5.9 (1.7)	3.0 (0.5)	9.2 (1.4)*	3.6 (0.8)	6.1 (1.3)	3.5 (0.5)	10.4 (1.6)*
15-HETrE ^j	1.5 (0.4)	2.7 (0.8)	3.1 (2.3)	23.6 (18.1)	1.2 (0.2)	2.1 (0.7)	0.7 (0.1)	2.7 (0.7)
9-HODE	41.9 (9.4)	86.9 (11.3)**	47.6 (12.4)	104.3 (19.9)**	34.5 (5.8)	86.1 (13.1)**	54.0 (16.0)	109.1 (18.3)**
13-HODE ^h	27.4 (4.5)	44.2 (5.5)*	30.2 (7.9)	50.0 (9.2)**	22.3 (3.1)	41.9 (5.9)**	26.9 (8.7)	46.0 (6.4)**

^aplacebo *n* = 18; ^bactive *n* = 11, placebo *n* = 6; ^cactive *n* = 9, placebo *n* = 7; ^dactive *n* = 12, placebo *n* = 8; ^eplacebo *n* = 19; ^factive *n* = 19, placebo *n* = 19; ^gactive *n* = 10, placebo *n* = 8; ^hplacebo *n* = 20; ⁱactive *n* = 4, placebo *n* = 9; ^jactive *n* = 4, placebo *n* = 5.

P* < 0.05, *P* < 0.01, ****P* < 0.001 compared to unexposed skin in the same group (Wilcoxon signed rank test).

There was no significant impact of GTC supplement on basal or UVR-induced eicosanoid concentrations.